Kura Oncology, Inc. (KURA): Valuation
TTM figures as of June 30, 2026
Kura Oncology, Inc. trades at a -11.59% free-cash-flow yield. That FCF yield is higher than 38% of its own month-end history back to 2015.
Earnings yield -29.29%. Net cash $509.2M.
132 month-end valuation observations are on file, starting September 2015.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is KURA cheap versus its own history?
Kura Oncology, Inc. trades at a -11.59% free-cash-flow yield. That FCF yield is higher than 38% of its own month-end history back to 2015.
What is KURA's free-cash-flow yield?
Kura Oncology, Inc. currently yields -11.59% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.